80年代土耳其译制电影,80年代外国电影|80年代外国电影有哪些_80年代外国经典电影在线播放地址是多少？

[1]鐘穎,鄒立,陳聲池.EGFR T790M突變豐度對阿美替尼治療晚期非小細胞肺癌療效的影響[J].福建醫(yī)藥雜志,2024,46(01):17-20.[doi:10.20148/j.fmj.2024.01.005]
　ZHONG Ying,ZOU Li,CHEN Shengchi.Relationship between abundance of EGFR T790M mutation and efficacy of Almonertinib in the treatment of advanced non-small cell lung cancer patients[J].FUJIAN MEDICAL JOURNAL,2024,46(01):17-20.[doi:10.20148/j.fmj.2024.01.005]
點擊復制

EGFR T790M突變豐度對阿美替尼治療晚期非小細胞肺癌療效的影響()
分享到：

《福建醫(yī)藥雜志》[ISSN:1002-2600/CN:35-1071/R]

卷:
46
期數(shù):
2024年01期
頁碼:
17-20
欄目:
臨床研究
出版日期:
2024-02-15

文章信息/Info

Title:
Relationship between abundance of EGFR T790M mutation and efficacy of Almonertinib in the treatment of advanced non-small cell lung cancer patients
文章編號:
1002-2600（2024）01-0017-04
作者:
鐘穎; 鄒立; 陳聲池
福建醫(yī)科大學附屬南平第一醫(yī)院，南平 353000
Author(s):
ZHONG Ying; ZOU Li;  CHEN Shengchi
Nanping First Hospital Affiliated to Fujian Medical University, Nanping, Fujian 353000, China
關鍵詞:
非小細胞肺癌; 阿美替尼; 突變豐度; 療效
Keywords:
non-small cell lung cancer;  Almonertinib;  mutation abundance;  efficacy
分類號:
R734.2
DOI:
10.20148/j.fmj.2024.01.005
文獻標志碼:
B
摘要:
目的分析阿美替尼治療晚期非小細胞肺癌療效，并探索EGFR T790M突變豐度與阿美替尼療效之間的關系。方法回顧性分析52例接受阿美替尼治療的經(jīng)一/二代EGFR-TKIs耐藥的Ⅲ期或Ⅳ期EGFR T790M突變的非小細胞肺癌患者，采用Kaplan-Meier法及Cox模型進行預后分析，并通過ROC曲線分析確定療效相關的T790M突變豐度臨界值。結果入組肺癌患者接受阿美替尼治療的ORR為48.1%，DCR為94.2%。外周血T790M豐度中位值為1.94%。阿美替尼治療患者的豐度最佳臨界值為2.05%，將突變豐度≥2.05%的患者納入高豐度組（25例），＜2.05%的患者納入低豐度組（27例），高豐度值和低豐度值的ORR分別為84.0%和14.8%，PFS分別為12.8個月和7.2個月，OS分別為22.2個月和18.3個月。Cox回歸分析顯示，基因類型、性別、吸煙史、是否腦轉移均不是阿美替尼治療患者PFS的影響因素，外周血EGFR T790M突變豐度是PFS的獨立影響因素。結論EGFR T790M突變豐度可能可預測阿美替尼治療的晚期EGFR T790M 突變NSCLC患者的有效率和生存期。
Abstract:
ObjectiveTo analyze the efficacy of Almonertinib in the treatment of advanced non-small cell lung cancer, and to explore the relationship between the abundance of EGFR T790M mutation and the efficacy of Almonertinib. MethodsA retrospective analysis of 52 patients with stage Ⅲ and stage-Ⅳ non-small cell lung cancer accompanied with EGFR T790M mutation who were treated with Almonertinib and were resistant to EGFR TKI in the first/second generation was carried out. The Kaplan-Meier method and Cox model were used to analyze the prognosis, and the critical value of T790M mutation abundance related to the efficacy was explored. ResultsThe ORR and DCR of the patients with lung cancer who received the treatment of Almonertinib were 48.1% and 94.2% respectively. The median abundance of T790M in peripheral blood was 1.94%.The cutoff value of abundance in patients treated with Almonertinib was 2.05%. Patients with mutation abundance≥2.05% were included in the high abundance group(25 cases), and patients with mutation abundance<2.05% were included in the low abundance group(27 cases). The ORR of the high abundance group and the low abundance group was 84.0% and 14.8% respectively, and the PFS was 12.8 months and 7.2 months respectively, and the OS was 22.2 months and 18.3 months respectively. Cox regression analysis showed that gene type, sex, smoking history, and brain metastasis were not factors influencing PFS in patients treated with Almonertinib, and the EGFR T790M mutation abundance in peripheral blood was an independent influencing factor of PFS. ConclusionThe abundance of EGFR T790M mutation may predict the effective rate and survival of patients with NSCLC with advanced EGFR T790M mutation treated with Almonertinib.

參考文獻/References:

[1] GAO S,LI N,WANG S,et al.Lung Cancer in People's Republic of China [J].Journal of Thoracic Oncology,2020,15(10):1567-1576.
[2] Hatami E,Nagesh P K B,Jaggi M,et al. Gambogic acid potentiates gemcitabine induced anticancer activity in non-small cell lung cancer[J].European Journal of Pharmacology,2020,888:173486.
[3] WU S G,SHIH J Y .Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer [J].Molecular Cancer,2018,17(1):38.
[4] MITSUDOMI T,SUDA K,YATABE Y.Surgery for NSCLC in the era of personalized medicine [J].Nature Reviews Clinical Oncology,2013,10(4):235-244.
[5] NAN X,XIE C,YU X Y,et al. EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer[J].Oncotarget,2017,8(43):75712-75726.
[6] LANGER C J.Epidermal growth factor receptor inhibition in mutation-positive non-small-cell lung cancer：is afatinib better or simply newer? [J].J Clin Oncol,2013,31(27):3303-3306.
[7] WU S G,SHIH J Y.Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer [J].Mol Cancer,2018,17(1):38.
[8] WU S G,LIU Y N,TSAI M F,et al.The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients [J].Oncotarget,2016,7(11).
[9]LU S,CAMIDGE R,YANG C,et al. P1.01-62 the third generation irreversible EGFR inhibitor HS-10296 in advanced non-small cell lung cancer patients[J].Journal of thoracic oncology:official publication of the International Association for the Study of Lung Cancer,2018,13(10)：S485.
[10] 邵宜,鐘殿勝.EGFR突變豐度的檢測及其臨床意義[J].中國肺癌雜志,2017,20(008):578-583.
[11] KEEDY V L,TEMIN S,SOMERFIELD M R,et al.ASCO provisional clinical opinion：epidermal growth factor receptor(EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy [J].Clin Oncol,2011,29(15):2121-2127.
[12] WANG W,SONG Z,ZHANG Y.A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR-TKI resistance [J].Cancer Medicine,2017,6(1):154-162.
[13] ZHOU Q,ZHANG X C,CHEN Z H,et al.Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer[J].Clin Oncol,2011,29(24)：3316-3321.
[14] YANG X,ZHUO M,YE X,et al. Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer[J].Oncotarget,2016,7(15)：20810-20824.
[15] IWAMA E,TAKAYAMA K,HARADA T,et al.Highly sensitive and quantitative evaluation of the EGFR T790M mutation by nanofluidic digital PCR[J].Oncotarget,2015,6(24)：20466-20473.
[16] 邵嵐,王文嫻,石志永,等.EGFR T790M突變豐度對奧希替尼治療晚期非小細胞肺癌療效的影響[J].腫瘤學雜志,2020,26(7):7.

相似文獻/References:

[1]林清華　吳聯(lián)平　劉加夫　陳友軒　 齊春能　林玉瓊　黃小紅　鄭　靜.晚期非小細胞肺癌患者胸水液基細胞學蠟塊中新抗體D5F3檢測的臨床價值[J].福建醫(yī)藥雜志,2019,41(01):3.
　LIN Qinghua,WU Lianping,LIU Jiafu,et al.Clinical value of D5F3 in hydrothorax fluid based cytological wax block in patients with advanced non-small cell lung cancer[J].FUJIAN MEDICAL JOURNAL,2019,41(01):3.
[2]陳新富 劉 寧 劉加夫.CK19在非小細胞肺癌淋巴結微轉移中的檢測價值(附90例分析)[J].福建醫(yī)藥雜志,2020,42(04):6.
　CHEN Xinfu,LIU Ning,LIU Jiafu..Detection value of CK19 in lymph node micrometastasis of NSCLC:analysis of 90 cases[J].FUJIAN MEDICAL JOURNAL,2020,42(01):6.
[3]林 瀟 陳愉生 李鴻茹.查爾森合并癥指數(shù)及簡化合并癥評分對晚期非小細胞肺癌預后的影響[J].福建醫(yī)藥雜志,2020,42(05):23.
　LIN Xiao,CHEN Yusheng,LI Hongru.Impact of Charlson comorbidity index and simplified comorbidity score on the prognosis of advanced non-small cell lung cancer[J].FUJIAN MEDICAL JOURNAL,2020,42(01):23.
[4]李榮賓,黃延延,林賢賓,等.IGF1/RPI3K/Akt通路及其調控對非小細胞肺癌血管生成擬態(tài)形成影響的研究[J].福建醫(yī)藥雜志,2023,45(03):112.
[5]黃陽,陳靜波,林貴山.動態(tài)監(jiān)測循環(huán)腫瘤細胞對寡轉移非小細胞肺癌聯(lián)合治療預后的價值[J].福建醫(yī)藥雜志,2023,45(05):8.
　HUANG Yang,CHEN Jingbo,LIN Guishan.Prognostic value of dynamic monitoring of circulating tumor cells in combination therapy for oligometastaticnon-small cell lung cancer[J].FUJIAN MEDICAL JOURNAL,2023,45(01):8.

更新日期/Last Update: 2024-02-15